Novo Nordisk shares fall 9% after Phase 3 ZEUS trial fails

Shares of Novo Nordisk fell sharply on Friday, July 31, 2026, after the Danish pharmaceutical company announced that its experimental heart drug ziltivekimab failed to meet its primary goal in a major Phase 3 clinical tr...

3 days agomarkets